U.S. Markets closed

Advaxis, Inc. (ADXS)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.03-0.04 (-0.66%)
At close: 4:00PM EDT
People also watch
ADROZIOPAGENFOLDBLCM

Advaxis, Inc.

305 College Road East
Princeton, NJ 08540
United States
609-452-9813
http://www.advaxis.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees90

Key Executives

NameTitlePayExercisedAge
Ms. Sara M. Bonstein MBAExec. VP, CFO & Corp. Sec.1.01MN/A36
Dr. Robert G. Petit Ph.D.Exec. VP & Chief Scientific Officer1.29MN/A57
Mr. Anthony A. LombardoInterim Chief Exec. OfficerN/AN/A68
Mr. Christopher DukeSr. VP & COON/AN/AN/A
Mr. Mayo PujolsSr. VP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. Its lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma. It has clinical trial collaboration agreements with Merck & Co., Inc. for the Phase I/II dose-escalation and safety study of ADXS31-142; and MedImmune, LLC to initiate a Phase I/II clinical study in the United States to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor. The company also has a licensing agreement with Global BioPharma Inc.; co-development and commercialization agreement with Especificos Stendhal SA de CV; and collaboration agreement with Amgen Inc. for the development and commercialization of ADXS-NEO, a preclinical investigational cancer immunotherapy treatment that activates patient’s immune system to respond against mutations or neoepitopes. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Corporate Governance

Advaxis, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 9. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.